Tech Company Financing Transactions
ViroCell Biologics Funding Round
On 8/15/2024, ViroCell Biologics landed investment from First Light Asset Management.
Transaction Overview
Company Name
Announced On
8/15/2024
Transaction Type
Debt
Amount
Unknown
Round
Undisclosed
Investors
First Light Asset Management (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its growth, as it continues to gain commercial traction with its specialist services in viral vector design and manufacturing.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
12-18 Theobalds Road
London, WC1X 8SL
UK
London, WC1X 8SL
UK
Phone
Website
Email Address
Overview
ViroCell Biologics is an innovation-driven CDMO focused exclusively on the design and GMP manufacture of lentiviral and gamma-retro viral vectors to enable novel cell and gene therapies to enter clinical trials. By leveraging Team ViroCell's 20+ year track record of manufacturing ~200 vectors, we are driven to accelerate the development of much-needed therapies so that disease can recede and progress can prevail.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 8/15/2024: Rx Save Card venture capital transaction
Next: 8/15/2024: Boosted.ai venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs